BFKB8488A

Phase 2Small molecule

Roche

BFKB8488A is one of 110 small molecule programs targeting Insulin resistance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Non-Alcoholic SteatohepatitisActive, not recruiting

Insulin ResistancePhase 1

Active, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 1

Active, not recruiting

Non-Alcoholic SteatohepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Edarbi

Takeda

Phase 3

1 2

Januvia

ZZydus Therapeutics Inc.

Phase 3

2 3

Jardiance

Boehringer Ingelheim

Phase 3

2 4

Parlodel

VVeroScience

Phase 3

1 5

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 6

Glucophage

Boehringer Ingelheim

Phase 3

1 7

Metformin Hcl

Boehringer Ingelheim

Phase 3

2 8

Avandia

GSK

Phase 3

1 9

GFT505

GGenfit

Phase 2

1 10

Pegylated IFN

KKaohsiung Veterans General Hospital.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

Terminated· Roche logo

Roche·Phase 2·NCT04171765·46 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

Completed· Roche logo

Roche·Phase 1·NCT03060538·154 enrolled

Insulin resistance1 trial

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

Completed· Roche logo

Roche·Phase 1·NCT02593331·79 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BFKB8488A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BFKB8488A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BFKB8488A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

BFKB8488A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Insulin resistance1 trial

References

Drug Info

Quick Facts

Related News